Pharmacopeia
ESMOLOL
Core pharmacology
- Indications Uses
- Short term management tachycardia and hypertension in a monitored patient
- For SVT termination- No intrinsic sympathomimetic activity or membrane stabilising properties
- Presentation
only available as an IV formulation.
presented as a clear liquid usually at a concentration of 10mg/ml- Physiological effects
It produces
decreases in heart rate and cardiac output and myocardial oxygen consumption- Adverse Effects Toxicity
- Care with: Opioids, Halo, OAD, CCB
- It is an irritant to veins and may lead to tissue necrosis with extravasation
- Absorption
bioavailabilty Only available as IV therefore 100%
- Distribution
lipid solubility is high so it crosses the BBB
- Protein binding
60% to albumin
- Volume of distribution
3.5 L/Kg
- Metabolism
neither hepatic or renal!
by red blood cell esterases to a mostly inactive metabolite- Excretion
urine
- Half-life
10 minutes
- Class Group
Ultra-short-acting selective beta1-adrenoceptor antagonist; Vaughan Williams class II antiarrhythmic.
- Introduction
Cardio-selective beta blocker with rapid onset and offset.
- Mechanism of action
Beta blockage leads to ↓Gs activity in receptor associated organs and
associated ↓in adenylyl cyclase and intracellular Ca2+.- Route And Dose
IV
dose In 10mg increments titrate to effect